针对哮喘的T细胞疗法

Targeting T cells for asthma.

作者信息

Heijink Irene H, Van Oosterhout Antoon J M

机构信息

Laboratory of Allergology and Pulmonary Diseases and Department of Pathology, University Medical Center Groningen (UMCG), Groningen University, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.

出版信息

Curr Opin Pharmacol. 2005 Jun;5(3):227-31. doi: 10.1016/j.coph.2005.04.002.

DOI:10.1016/j.coph.2005.04.002

PMID:15907907

Abstract

The type 2 T-helper (Th2) lymphocyte can be regarded as an important target cell for the treatment of allergic asthma as it plays a crucial role in the initiation, progression and persistence of disease. Several strategies to target Th2 cells can be envisioned. Drugs that prevent Th2-cells from migrating into the lung tissue, such as antibodies to the chemokine receptor CCR4 and inhibitors of the adhesion molecule VLA-4, are promising for the treatment of asthma. To inhibit Th2-cell activation, novel asthma drugs that act on Th2-selective transciption factors such as GATA3 are being developed. Although initial strategies aimed to block the action of Th2-derived cytokines, the generation of counter-regulatory Th1 lymphocytes and regulatory T cells is currently being explored.

摘要

2型辅助性T（Th2）淋巴细胞可被视为治疗过敏性哮喘的重要靶细胞，因为它在疾病的起始、进展和持续过程中起着关键作用。可以设想几种针对Th2细胞的策略。能够阻止Th2细胞迁移到肺组织的药物，如趋化因子受体CCR4抗体和黏附分子VLA-4抑制剂，有望用于哮喘治疗。为抑制Th2细胞活化，正在研发作用于Th2选择性转录因子（如GATA3）的新型哮喘药物。尽管最初的策略旨在阻断Th2衍生细胞因子的作用，但目前正在探索产生反调节性Th1淋巴细胞和调节性T细胞的方法。